TransMedics Group, Inc.
$113.13
▲
0.29%
2026-04-21 09:50:01
www.transmedics.com
NGM: TMDX
Explore TransMedics Group, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$3.88 B
Current Price
$113.13
52W High / Low
$156 / $84.53
Stock P/E
20.39
Book Value
$13.81
Dividend Yield
—
ROCE
11.09%
ROE
54.24%
Face Value
—
EPS
$4.87
Exp Qtr EPS
—
Sector
Healthcare
Industry
Medical Devices
Employees
898
Beta
2.08
Debt / Equity
109.76
Current Ratio
7.14
Quick Ratio
6.59
Forward P/E
30.95
Price / Sales
6.46
Enterprise Value
$3.94 B
EV / EBITDA
29.31
EV / Revenue
6.51
Rating
Buy
Target Price
$156.1
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Short-term liquidity looks comfortable.
- Net margin remains healthy.
Cons
- Some data points may be missing or delayed because the source is not an official exchange feed.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Cytek Biosciences, Inc. | $4.57 | — | $592.62 M | — | -10.52% | -18.05% | $6.18 / $2.37 | $2.66 |
| 2. | Lifeward Ltd. | $7.52 | — | $11.49 M | — | -155.52% | -1.46% | $18.6 / $4.14 | $5.52 |
| 3. | Inspire Medical Systems, Inc. | $56.97 | 11.28 | $1.64 B | — | 6.28% | 19.77% | $163.35 / $48.3 | $27.33 |
| 4. | Glaukos Corporation | $123.8 | — | $7.27 B | — | -25.2% | -26.38% | $130.23 / $73.16 | $11.41 |
| 5. | Beta Bionics, Inc. | $12.91 | — | $576.08 M | — | -24.07% | -40.26% | $32.71 / $8.8 | $6.48 |
| 6. | Insulet Corporation | $193.4 | 55.6 | $13.48 B | — | 18.87% | 18.12% | $354.88 / $194.61 | $21.53 |
| 7. | Sight Sciences, Inc. | $4.36 | — | $220.88 M | — | -35.58% | -50.74% | $9.24 / $2.4 | $1.2 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 160.76 M | 143.82 M | 157.37 M | 143.54 M | 121.62 M | — |
| Operating Profit | 21.27 M | 23.3 M | 36.57 M | 27.44 M | 8.64 M | — |
| Net Profit | 105.38 M | 24.32 M | 34.91 M | 25.68 M | 6.86 M | — |
| EPS in Rs | 3.07 | 0.71 | 1.02 | 0.75 | 0.2 | 0.12 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 605.49 M | 441.54 M | 241.62 M | 93.46 M |
| Operating Profit | 108.58 M | 37.5 M | -28.73 M | -31.44 M |
| Net Profit | 190.29 M | 35.46 M | -25.03 M | -36.23 M |
| EPS in Rs | 5.55 | 1.03 | -0.73 | -1.06 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 1.07 B | 804.08 M | 706.05 M | 277.15 M |
| Total Liabilities | 595.27 M | 575.47 M | 568.85 M | 89.77 M |
| Equity | 473.1 M | 228.6 M | 137.2 M | 187.38 M |
| Current Assets | 637.78 M | 497.22 M | 510.65 M | 252.29 M |
| Current Liabilities | 89.31 M | 59.91 M | 54.93 M | 23.66 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 192.84 M | 48.8 M | -13.03 M | -45.82 M |
| Investing CF | -59.25 M | -129.3 M | -193.95 M | 54.51 M |
| Financing CF | 16.86 M | 22.87 M | 400.42 M | 167.93 M |
| Free CF | 133.59 M | -80.94 M | -192.09 M | -57.72 M |
| Capex | -59.25 M | -129.74 M | -179.06 M | -11.91 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 82.74% | 158.53% | — | — |
| Earnings Growth % | 241.7% | 30.92% | — | — |
| Profit Margin % | 8.03% | -10.36% | -38.77% | — |
| Operating Margin % | 8.49% | -11.89% | -33.64% | — |
| Gross Margin % | 59.36% | 63.77% | 69.84% | — |
| EBITDA Margin % | 15.84% | -3.19% | -30.99% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.